

PUBBLICAZIONI SCIENTIFICHE 2024 DEL CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI, FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO

	TITOLO PAPER	AUTORI	RIVISTA	ANNO	VOLUME	ISSUE	PAGINE		DOI	TIPO DI PUBBLICAZIONE
1	Flow-chamber device (T-TAS) to diagnose patients suspected of platelet function defects.	Leccchi A, La Marca S, Padovan L, Boscarino M, Peyvandi F, Tripodi A.	Blood Transfusion	2024	22	1	55	64	10.2450/2023.0208-22	Articolo originale
2	Clinical and laboratory presentation and underlying mechanism in patients with low VWF	Seidzadeh O, Ciavarella A, Baronciani L, Boggio F, Ballardini F, Cozzi G, Colpani P, Pagliari MT, Novembrino C, Siboni SM, Peyvandi F.	Thrombosis and Haemostasis	2024	124	4	340	350	10.1055/a-2186-6362	Articolo originale
3	Predicting survival in patients with 'non-high-risk' acute variceal bleeding receiving β -blockers+ligation to prevent re-bleeding.	Balcar L, Mandorfer M, Hernández-Gea V, Procopet B, Meyer EL, Giráldez Á, Amitrano L, Villanueva C, Thabut D, Samaniego LJ, Silva-Junior G, Martínez J, Genescá J, Bureau C, Trebicka J, Llop Herrera E, Laleman W, Palazón Azorín JM, Castellote Alonso J, Gluud LL, Noronha Ferreira C, Cañete N, Rodríguez M, Ferlitsch A, Mundi JL, Grønbaek H, Hernandez Guerra MN, Sassatelli R, Dell'Era A, Senzolo M, Abraldes JG, Romero-Gómez M, Zipprich A, Casas M, Masnou H, Primignani M, Krag A, Nevens F, Calleja JL, Jansen C, Vega Catalina M, Albillos A, Rudler M, Tapias EA, Guardascione MA, Tantau M, Schwarzer R, Reiberger T, Laursen SB, Lopez-Gomez M, Cachero A, Ferrarese A, Ripoll C, La Mura V, Bosch J, García-Pagán JC, International Variceal Bleeding Observational Study Group by the Baveno Cooperation: an EASL consortium.	Journal of Hepatology	2024	80	1	73	81	10.1016/j.jhep.2023.10.007	Multicentrico NO PROFIT
4	Open ADAMTS13 conformation index predicts earlier relapse in immune-mediated thrombotic thrombocytopenic purpura.	De Waele L, Sakai K, Mancini I , Sinkovits G, Falter T, Inoue T, Agosti P , Rossmann H, Von Auer C, Tersteeg C, De Meyer SF, Joly BS, Veyradier A, Coppo P, Fijnheer R, Peyvandi F , Prohászka Z, Lämmle B, Vanhoorelbeke K.	Journal of Thrombosis and Haemostasis	2024	22	2	493	502	10.1016/j.jtha.2023.10.014	Articolo originale
5	How we manage a high D-dimer.	Franchini M, Focosi D, Pezzo MP, Mannucci PM.	Haematologica	2024	109	4	1035	1045	10.3324/haematol.2023.283966	Review/linee Guida
6	Development and validation of the Medical Attitudes Towards Deprescribing Questionnaire.	Agosti P , D'Avanzo B, Monti I, Cortesi L, Nobili A, Tettamanti M.	Internal and Emergency Medicine	2024	19	2	413	422	10.1007/s11739-023-03489-0.	Articolo originale
7	Landmark endorsement of a global registry: The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), publicly endorses World Federation of Hemophilia Gene Therapy Registry as global standard.	Konkle BA, Peyvandi F , Coffin D, Naccache M, Youttananakorn T, Pierce GF; WFH Gene Therapy Registry Scientific Advisory Board.	Haemophilia	2024	30	1	232	235	10.1111/hae.14912	Lettera con dati
8	Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial.	Pipe SW MD, Collins PW, Dhalluin C, Kenet G, Schmitt C, Buri M, Jiménez-Yuste V, Peyvandi F , Young G, Oldenburg J, Mancuso ME, Kavakli K, Kialainen A, Deb S, Niggl M, Chang T, Lehle M, Fijnvandraat K	Blood	2024	143	14	1355	1364	10.1182/blood.2023021832.	Trial Profit
9	Knowledge and attitudes toward gene therapy of a cohort of Italian patients with hemophilia	Cutica I, Mortarino M, Garagiola I, Pravettoni G, Peyvandi F.	Journal of Thrombosis and Haemostasis	2024	22	4	1001	1008	10.1016/j.jtha.2023.12.018	Articolo originale
10	Defining a metrologically traceable and sustainable calibration hierarchy of International Normalized Ratio (INR) for monitoring of vitamin K antagonist treatment in accordance with International Standard ISO 17511:2020: Communication from the IFCC-SSC/ISTH working group on PT/INR standardization.	van den Besselaar AMHP, Stavelin A, Kitchen S, Bryant M, Tripodi A, Scalabrino E, Clerici M , Herbel P, Jünschke A, Meyer Dos Santos S, Meijer P, Niessen RWLM, Meijers JCM, Thelwell C, Cuker A, Kung C, Cao Z, Zander N, Iwasaki Y, Depasse F, van Rijn C, Baktawar S, Abdoel C, Cobbaert CM.	Journal of Thrombosis and Haemostasis	2024	22	4	1236	1248	10.1016/j.jtha.2023.12.013	Review/linee Guida
11	Emicizumab: the hemophilia A game changer.	Alcedo Andrade PE, Mannucci PM , Kessler CM.	Haematologica	2024	109	5	1334	1347	10.3324/haematol.2022.282099.	Review/linee Guida
12	Health and the Environment: Messages for the Cardiologist.	Mannucci PM.	European Journal of Preventive Cardiology	2024	31	1	128	130	10.1093/eurjpc/zwad343	Editoriale
13	A European National Health and Social Service model: the S of social.	Garattini L, Nobili A, Mannucci PM.	Internal and Emergency Medicine	2024	19	1	233	235	10.1007/s11739-023-03483-6	Lettera opinion
14	Efficacy and safety of tranexamic acid in acute haemorrhage.	Franchini M, Focosi D, Zaffanello M, Mannucci PM.	BMJ	2024	384				10.1136/bmj-2023-075720.	Review/linee Guida
15	Treatment of immune-mediated thrombotic thrombocytopenic purpura without plasma exchange	Capecchi M, Gazzola G, Agosti P, De Leo P, Mancini I, Ferrari B, Giannotta JA, Artoni A, Peyvandi F	Haematologica	2024	109	6	2019	2023	10.3324/haematol.2023.284438	Case Report
16	Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors.	Castaman G, Peyvandi F , Kremer Hovinga JA, Schutgens REG, Robson S, Moreno K, Jiménez-Yuste V.	TH Open	2024	8	1	e42	e54	10.1055/s-0043-1777766	Trial Profit
17	Pattern of use and clinical outcomes with rIX-FP in pediatric/adolescent patients with haemophilia B in Italy: Results from IDEAL real-world study.	Giordano P, Pollio B, Sottillotta G, Biasoli C, Daniele F, De Cristofaro R, Peyvandi F , Villa MR, Castaman G; IDEAL Study Group.	European Journal of Haematology	2024	112	5	765	775	10.1111/ejh.14168.	Multicentrico Profit
18	Recommendations for a minimum data set for monitoring gene therapy in hemophilia: Communication from the ISTH SSC Working Group on Gene Therapy.	Miesbach W, Konkle B, Chowdary P, Kaczmarek R, Leebeek F, Mahlangu J, Makris M, Pipe SW, Srivastava A, Voorberg J, Pierce GF, Peyvandi F.	Journal of Thrombosis and Haemostasis	2024	22	5	1510	1515	10.1016/j.jtha.2023.12.039	Review/linee Guida
19	Evolution of spontaneous portosystemic shunts over time and following aetiological intervention in patients with cirrhosis.	Vidal-González J, Martínez J, Mula A, López M, Baiges A, Elmahdy A, Lampichler K, Maleux G, Chang J, Poncela M, Low G, Ghigliazza G, Zipprich A, Picón C, Shah R, Llop E, Darnell A, Maurer MH, Bonne L, Ramón E, Quiroga S, Abraldes JG, Krag A, Trebicka J, Ripoll C, La Mura V , Tandon P, García-Martínez R, Praktiknjo M, Laleman W, Reiberger T, Berzigotti A, Hernández-Gea V, Calleja JL, Tsochatzis EA, Albillos A, Simón-Talero M, Genescá J; Baveno VI-SPSS group from the Baveno Cooperation.	JHEP Reports	2024	6	2			10.1016/j.jhepr.2023.100977	Multicentrico NO PROFIT
20	Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern Italy.	Lombardi A, Villa S, Colaneri M, Scaglione G, Bai F, Varisco B, Bono V, Vena A, Dentone C, Russo C, Tettamanti M, Renisi G, Viero G, Azzarà C, Mantero M, Peyvandi F , Bassetti M, Marchetti G, Muscatello A, Nobili A, Gori A, Bandera A; "COVID19 NETWORK"	Journal of Infection and Public Health	2024	17	3	467	473	10.1016/j.jiph.2023.12.026	Multicentrico NO PROFIT
21	Congenital fibrinogen disorders: a retrospective clinical and genetic analysis of the Prospective Rare Bleeding Disorders Database.	Mohsenian S, Palla R, Menegatti M, Cairo A, Leccchi A , Casini A, Neerman-Arbez M, Asselta R, Scardo S, Siboni SM , Blatný J, Zapletal O, Schved JF, Giansily-Blaizot M, Halimeh S, Daoud A, Platokouki H, Pergantou H, Schutgens REG, Haaften-Spoor MV, Brons P, Laros-van Gorkom BAP, Pinxten EV, Borhany M, Fatima N, Mikovic D, Saracevic M MD, Özdemir GN, Ay Y, Makris M, Lockley C, Mumford AD, Harvey A, Austin SK, Shapiro AD, Williamson A, McGuinn C, Goldberg J, de Moerloose P, Peyvandi F.	Blood Advances	2024	8	6	1392	1404	10.1182/bloodadvances.2023012186	Articolo originale
22	Outcome of atypical hemolytic uremic syndrome: role of triggers and complement abnormalities in the response to C5 inhibition.	Ardissino G, Cresseri D, Mancuso MC, Capone V, Porcaro L, Amico V, Tangredi M, Grovetti E, Griffini S , Castellano G, Montini G, Consonni D, Cugno M; HUS-ItaKid Network.	Journal of Nephrology	2024	37	4	1017	1026	10.1007/s40620-023-01873-9	Multicentrico NO PROFIT

23	Evaluation of an automated platelet aggregation method for detection of congenital or acquired platelet function defects.	Lecchi A, Capecechi M, Padovan L, Artoni A, Arai N, Shinohara S, La Marca S, Peyvandi F.	Blood Transfusion	2024	22	4	350	359	10.2450/BloodTransfus.601	Articolo originale
24	Type 2M/2A von Willebrand disease: A shared phenotype between type 2M and 2A.	Seidzadeh O, Mollica L, Zambarbieri S, Baronciani L, Cairo A, Colpani P, Cozzi G, Pagliari MT, Ciavarella A, Siboni SM, Peyvandi F.	Blood Advances	2024	8	7	1725	1736	10.1182/bloodadvances.2024012626.	Articolo originale
25	Ultrasound evaluation of hemophilic arthropathy: a proposal of definitions in a changing landscape.	Gualtierotti R, Solimeno LP, Peyvandi F; Ultrasound in hemophilic arthropathy study group.	Research and Practice in Thrombosis and Haemostasis	2024	3	8			10.1016/j.rpth.2023.102314	Editoriale
26	Statins, ACE/ARBs drug use, and risk of pneumonia in hospitalized older patients: a retrospective cohort study.	Franchi C, Rossio R , Mandelli S, Ardoino I, Nobili A, Peyvandi F , Mannucci PM ; REPOSI Investigators.	Internal and Emergency Medicine	2024	19	3	689	696	10.1007/s11739-023-03528-w	Multicentrico NO PROFIT
27	Safety and efficacy of combined dual antiplatelet therapy and factor VIII prophylaxis in patients with haemophilia A after acute coronary syndrome.	Agosti P, Siboni SM, Ciavarella A, Arcudi S, Boggio F, Gualtierotti R, Peyvandi F.	Haemophilia	2024	30	2	344		10.1111/hae.14963.	Articolo originale
28	Tranexamic Acid: An Evergreen Hemostatic Agent.	Franchini M, Focosi D, Mannucci PM.	Seminars in Thrombosis and Hemostasis	2024	50	5	733	738	10.1055/s-0044-1779632	Review/linee Guida
29	Contact system activation and bradykinin generation in patients with idiopathic angioedema	Suffritti C , Calzari P, Depetri F, Griffini S, Grovetti E , Santacroce R, Margaglione M, Cugno M.	Journal of Investigational Allergology & Clinical Immunology	2024	34	5	333	335	10.18176/jiaci.0996	Lettera con dati
30	Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies.	Di Minno G, Miesbach W, Castaman G, Peyvandi F.	Haematologica	2024	109	12	3879	3891	10.3324/haematol.2023.284622	Review/linee Guida
31	Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis (ATLAS-PPX).	Kenet G, Nolan B, Zülfikar OB, Antmen B, Kampmann P, Matsushita T, You CW, Vilchevska K, Bagot CN, Sharif A, Peyvandi F , Young G, Negrier CG, Chi J, Kittner B, Susebach C, Shamma F, Mei B, Andersson SR, Kavakli K.	Blood	2024	143	22	2256	2269	10.1182/blood.2023021864	Trial Profit
32	EAHAD haemophilia gene therapy clinical outcome database (EAHAD-GTD).	Miesbach W, Boban A, Chowdary P, Coppens M, Crato M, Jimenez-Yuste V, Klamroth R, Makris M, Mulders G, Peyvandi F.	Haemophilia	2024	30	3	852	854	10.1111/hae.14981	Lettera con dati
33	How the Hemostasis Laboratory Can Help Clinicians to Manage Patients on Oral Anticoagulants.	Tripodi A, Clerici M, Scalabrino E, Agosti P, Bucciarelli P, Peyvandi F.	Mediterranean Journal of Hematology and Infectious Diseases	2024	16	1			10.4084/MJHID.2024	Review/linee Guida
34	Rare bleeding disorders: Advances in management.	Casini A, Al-Samkari H, Hayward C, Peyvandi F.	Haemophilia	2024	30	Suppl 3	60	69	10.1111/hae.14986.	Review/linee Guida
35	Administration of gene therapy for haemophilia - The hub and spoke model and its regional differences and challenges.	Miesbach W, Boban A, Chowdary P, Coppens M, Crato M, Jimenez-Yuste V, Klamroth R, Makris M, Mulders G, Peyvandi F.	Haemophilia	2024	30	3	855	857	10.1111/hae.14985	Lettera con dati
36	Low-dose emicizumab for more equitable access to prophylaxis in resource limited countries.	Mannucci PM , Hermans C.	Haemophilia	2024	30	3	575	576	10.1111/hae.14968	Commento/editoriale di commento
37	Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillations: the MAS study.	Testa S, Palareti G, Legnani C, Dellanoce C, Cini M, Paoletti O, Ciampa A, Antonucci E, Poli D, Morandini R, Tala M, Chiarugi P, Santoro RC, Iannone AM, De Candia E, Pignatelli P, Faioni EM, Chistolini A, Esteban MDP, Marietta M, Tripodi A , Tosetto A	Blood Advances	2024	8	8	1846	1856	10.1182/bloodadvances.2023012408	Multicentrico NO PROFIT
38	The value-based healthcare approach to haemophilia: Development of outcome measures for the evaluation of care of people with haemophilia.	Cortesi PA, Fornari C, Conti S, Pollio B, Boccalandro E , Buzzi A, Carulli C, Coppola A, De Cristofaro R, Di Minno MND, Dolan G, Ferri Grazi E, Fornari A, Gualtierotti R , Hermans C, Jiménez-Juste V, Kenet G, Lupi A, Martinoli C, Mansueto MF, Nicolò G, Tagliaferri A, Gringeri A, Molinari AC, Mantovani LG, Castaman G; V.B.H. project group.	Haemophilia	2024	30	2	437	448	10.1111/hae.14943	Multicentrico NO PROFIT
39	Post-lumbar puncture cerebral vein thrombosis.	Marasco V, Gianniello F , Paolucci A, Martinelli I, Capecci M.	eJHaem	2024	5	1	222	224	10.1002/jha2.803	Case Report
40	Predictive parameters for spontaneous joint bleeding during emicizumab prophylaxis.	Arcudi S, Gualtierotti R, Scalabrino E, Clerici M, Hassan S, Begnozzi V, Boccalandro EA, Novembrino C, Valsecchi C, Palla R, Peyvandi F.	Blood Advances	2024	8	11	2901	2907	10.1182/bloodadvances.2023012285	Articolo originale
41	Portal hypertension-like pattern in coronavirus disease 2019 acute respiratory distress syndrome.	Dondossola D, Lonati C, Pini A, Bignamini D, Zanella A, Lombardi R, Scaravilli V, La Mura V , Forzenigo L, Biondetti P, Grasselli G, Fracanzani A; PH-COVID collaborator group ; Paleari C, Cespiati A, Todaro S, Cattaneo E, Di Felicianantonio M, Sigon G, Valsecchi C, Guzzardella A, Battistin M, Iuculano F.	Journal of Critical Care	2024	82	August 2024			10.1016/j.jcrc.2024.154759	Multicentrico NO PROFIT
42	Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in individuals with steatotic liver disease.	Marchetti A, Pelusi S, Marella A, Malvestiti F, Ricchiuti A, Ronzoni L, Lionetti M, Moretti V, Bugianesi E, Miele L, Vespasiani-Gentilucci U, Dongiovanni P, Federico A, Soardo G, D'Ambrosio R, McCain MV, Reeves HL, La Mura V , Prati D, Bolli N, Valenti L; EPIDEMIC Study Investigators.	Hepatology	2024	80	4	816	827	10.1097/JEP.0000000000000839	Multicentrico NO PROFIT
43	Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B.	Lemons R, Wang M, Curtin J, Lepatan LM, Male C, Peyvandi F , von Depka Prondzinski M, Wang R, McKeand W, Seifert W, Oldenburg J.	TH Open	2024	8	1	e155	e163	10.1055/s-0044-1781466.	Trial Profit
44	Comprehensive investigation of platelet function in patients with cirrhosis. Immune gene polymorphisms associated with poor response to platelet transfusion and recombinant factor VII administration in Glanzmann thrombasthenia.	Lecchi A, Tosetti G, Ghali C, La Marca S, Clerici M, Padovan L , Femia EA, Primignani M, La Mura V , Lampertico P, Peyvandi F, Tripodi A.	Thrombosis Research	2024	237	/	64	70	10.1016/j.thromres.2024.03.017.	Articolo originale
45	Predicting inhibitor development using a random peptide phage-display library approach in the SIPPET Cohort.	Naderi M, Mirzaei I, Seidzadeh O , Moud AP, Sarani H, Avan A, Taheri M, Jahantigh D, Keramati MR, Sohrabi T.	Haemophilia	2024	30	3	752	764	10.1111/hae.14971	Articolo originale
46	Factor VIII and von Willebrand factor are wavering proteins: the basis for the therapeutic development of desmopressin.	Hassan S, Baselli G, Mollica L, Rossi RL PhD, Chand H , El-Beshlawy AM, Elafly MS, Ramanan V, Eshghi P, Karimi M, Palla R , Rosendaal FR, Peyvandi F.	Blood Advances	2024	8	11	2880	2889	10.1182/bloodadvances.2023011388.	Articolo originale
47	Real-World Data Analysis of Patients Affected by Immune-Mediated Thrombotic Thrombocytopenic Purpura in Italy.	Mannucci PM, Siboni SM.	Research and Practice in Thrombosis and Haemostasis	2024	8	2			10.1016/j.rpth.2024.102369	Commento/editoriale di commento
48	Three-year outcomes of valoctocogene roxaparovene gene therapy for hemophilia A.	Angelucci E, Artoni A , Fianchi L, Dovizio M, Iacolare B, Saragoni S, Esposti LD.	Journal of Clinical Medicine	2024	13	5			10.3390/jcm13051342	Articolo originale
49	Gender equity in hemophilia: need for healthcare, familial, and societal advocacy.	Madan B, Ozelo MC, Raheja P, Symington E, Quon DV, Leavitt AD, Pipe SW, Lowe G, Kenet G, Reding MT, Mason J, Wang M, von Drygalski A, Klamroth R, Shapiro S, Chambost H, Dunn AL, Oldenburg J, Chou SC, Peyvandi F , Millar CM, Osmond D, Yu H, Dashiell-Aje E, Robinson TM, Mahlangu J.	Journal of Thrombosis and Haemostasis	2024	22	7	1880	1893	10.1016/j.jth.2024.04.001	Trial Profit
50	ISTH's new strategic plan 2024-2028: A transformative journey toward shaping the future of thrombosis and hemostasis.	Gualtierotti R, Garagiola I, Mortarino M, Spens S, Romero-Lux O, Peyvandi F.	Frontiers in Medicine (Lausanne)	2024	11				10.3389/fmed.2024.1345496	Review/linee Guida
51		Peyvandi F , Anchaisuksiri P, Reiser T.	Journal of Thrombosis and Haemostasis	2024	22	6	1525	1527	10.1016/j.jth.2024.04.013	Editoriale

52	Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A.	Agarwal S, Hermans C, Miesbach W, Peyvandi F , Sidonio R Jr, Osmond D, Newman V, Henshaw J, Pipe S.	Haemophilia	2024	30	4	905	913	10.1111/hae.15025	Articolo originale
53	Assessing joint health in haemophilia patients: The combined value of physical examination and ultrasound imaging.	Gualtierotti R, Giachi A, Truma A, Arcudi S, Ciavarella A, Bucciarelli P , Consonni D, Boccalandro E, Begnozzi V , Solimeno LP, Siboni SM, Peyvandi F .	Haemophilia	2024	30	4	1018	1024	10.1111/hae.15030	Articolo originale
54	D-dimer for patients on VKA vs DOAC. Impact on the validity of D-dimer to make decision for extended anticoagulation.	Tripodi A, Capecchi M, Scalabrino E, Clerici M, Scimeca B, Agosti P, Bucciarelli P, Peyvandi F .	Blood Advances	2024	8	14	3612	3614	10.1182/bloodadvances.2024013193	Lettera con dati
55	Practical Suggestions for an Optimal Management of Vitamin K Antagonists: Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies (FCSA) Position Paper.	Gallazzo S, Bucciarelli P , Barcellona D, Ciampa A, Grandone E, Malcangi G, Rescigno G, Squizzato A, Toschi V, Testa S, Poli D.	Thrombosis and Haemostasis	2024	124	8	803	809	10.1055/s-0044-1782688	Review/linee Guida
56	Coma in adult cerebral venous thrombosis: The BEAST study	Ranjan R, Ken-Dror G, Martinelli I , Grandone E, Hiltunen S, Lindgren E, Margaglione M, Duchez VLC, Triquenot Bagan A, Zedde M, Giannini N, Ruigrok YM, Worrall BB, Majersik JJ, Putaala J, Haapaniemi E, Zuurbier SM, Brouwer MC, Passamonti SM, Abbattista M, Bucciarelli P , Lemmens R, Pappalardo E , Costa P, Colombi M, Aguiar de Sousa D, Rodrigues S, Canhão P, Tkach A, Santacroce R, Favuzzi G, Arauz A, Colaizzo D, Spengos K, Hodge A, Ditta R, Pezzini A, Coutinho JM, Thijs V, Jood K, Tatlisumak T, Ferro JM, Sharma P.	European Journal of Neurology	2024	31	8	e16311		10.1111/ene.16311	Multicentrico NO PROFIT
57	Prediction of venous thromboembolism in average-risk, young candidates for oral contraceptive use: to genotype, or not to genotype, that is the question	Vercellini P, Artoni A, Abbattista M , Martinelli I, Pillinini C, Forzano F.	American Journal of Obstetrics & Gynecology	2024	231	2	e78	e79	10.1016/j.ajog.2024.04.038	Lettera con dati
58	Testosterone therapy does not affect coagulation in male hypogonadism: a longitudinal study based on thrombin generation.	Lanzi V, Indirli R, Tripodi A, Clerici M , Bonomi M, Cangiano B, Petria I, Arosio M, Mantovani G, Ferrante E.	Journal of Clinical Endocrinology & Metabolism	2024	109	12	3186	3195	10.1210/clinem/dgae317	Articolo originale
59	Lung donor bronchoalveolar lavage positivity: incidence, risk factors, and lung transplant recipients' outcome.	Fumagalli J, Punzi V, Scaravilli V, Passamonti SM , Morlacchi LC, Rossetti V, Maraschini A, Matinato C, Brivio M, Righi I, Blasi F, Bandera A, Rosso L, Panigada M, Zanella A, Grasselli G.	Journal of Heart and Lung Transplantation	2024	43	8	1288	1297	10.1016/j.healun.2024.04.005	Articolo originale
60	Response to the Comment: "Advocating prudent D-dimer testing: constructive perspectives and comments on "How we manage a high D-dimer".	Franchini M, Focosi D, Pezzo MP, Mannucci PM .	Haematologica	2024	109	10	3454		10.3324/haematol.2024.285769	Commento/editoriale di commento
61	Anticoagulant therapy in pregnant women with mechanical heart valves: Italian FCSA Position Paper.	Campello E, Bucciarelli P , Catalani F, Erba N, Squizzato A, Poli D.	Thrombosis and Haemostasis	2024	124	8	695	708	10.1055/a-2325-5658	Review/linee Guida
62	Bleeding and thrombotic events and intensity of heparin therapy in the two first waves of COVID-19.	Rossio R , Tettamanti M, Galbusera AA, Gualtierotti R, Giachi A , Torri A, Montano N, Fracanzani AL, Bandera A, Nobili A, Peyvandi F ; COVID-19 Network.	Internal and Emergency Medicine	2024	19	6	1577	1583	10.1007/s11739-024-03635-2	Multicentrico NO PROFIT
63	Application of genetic testing for the diagnosis of von Willebrand disease.	Seidzadeh O, Baronciani L , Lillicrap D, Peyvandi F .	Journal of Thrombosis and Haemostasis	2024	22	8	2115	2128	10.1016/j.jtha.2024.05.006	Review/linee Guida
64	A case of lymphadenopathies with concomitant multiple acquired hemostasis disorders in an adult female patient.	Truma A, Artoni A, Giannotta JA , Caronni M, Peyvandi F .	Internal and Emergency Medicine	2024	19	7	1971	1974	10.1007/s11739-024-03652-1	Case Report
65	IgM autoantibodies to complement factor H in C3 glomerulopathy.	Cugno M , Mancuso MC, Depetri F, Peyvandi F , Ardissino G.	Journal of Nephrology	2024	37	5	1415	1416	10.1007/s40620-024-01961-4	Lettera con dati
66	Drug prescription appropriateness in hospitalized older patients: 15-year results and lessons from a countrywide register.	Nobili A, Mannucci PM ; REPOSI Investigators.	Internal and Emergency Medicine	2024	19	6	1549	1556	10.1007/s11739-024-03645-0	Review/linee Guida
67	More early bleeds associated with high baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study	Palareti G, Testa S, Legnani C, Dellanoce C, Cini M, Paoletti O, Ciampa A, Antonucci E, Poli D, Morandini R, Tala M, Chiarugi P, Santoro RC, Iannone AM, De Candia E, Pignatelli P, Faioni EM, Chistolini A, Esteban MDP, Marietta M, Tripodi A , Tosetto A.	Blood Advances	2024	8	18	4913	4923	10.1182/bloodadvances.2024013126	Articolo originale
68	Gene-Gene Interaction Between Factor-XI and ABO Genes in Cerebral Venous Thrombosis: The BEAST Study.	Ken-Dror G, Martinelli I , Grandone E, Hiltunen S, Lindgren E, Margaglione M, Le Cam Duchez V, Triquenot AB, Zedde M, Mancuso M, Ruigrok YM, Worrall BB, Majersik JJ, Putaala J, Haapaniemi E, Zuurbier S, Brouwer MC, Passamonti SM, Abbattista M, Bucciarelli P , Lemmens R, Pappalardo E , Costa P, Colombi M, De Sousa DA, Rodrigues SG, Canhao P, Tkach A, Santacroce R, Favuzzi G, Arauz A, Colaizzo D, Spengos K, Hodge A, Ditta R, Pezzini A, Coutinho JM, Thijs VN, Jood K, Pare G, Tatlisumak T, Ferro JM, Sharma P.	Neurology	2024	102	11			10.1212/WNL.0000000000209445.	Multicentrico NO PROFIT
69	Exploring nonreplacement therapies' impact on hemophilia and other rare bleeding disorders	Peyvandi F, Seidzadeh O, Mohsenian S, Garagiola I .	Research and Practice in Thrombosis and Haemostasis	2024	8	4			10.1016/j.rpth.2024.102434	Review/linee Guida
70	Global Prevalence of Hereditary Thrombotic Thrombocytopenic Purpura Determined by Genetic Analysis.	Seidzadeh O, Cairo A, Mancini I , George JN, Peyvandi F .	Blood Advances	2024	8	16	4386	4396	10.1182/bloodadvances.2024013421.	Articolo originale
71	Variant p.Tyr1584Cys: a frequent von Willebrand factor variant in search of von Willebrand disease.	Seidzadeh O, Baronciani L, Colpani P, Cozzi G, Ciavarella A, Siboni SM, Peyvandi F .	Research and Practice in Thrombosis and Haemostasis	2024	8	4			10.1010.1016/j.rpth.2024.102451.16/j.rpth.2024.102451.	Lettera con dati
72	Pros and cons of the ISTH treatment guidelines for hemophilia.	Mannucci PM .	Journal of Thrombosis and Haemostasis	2024	22	9	2413	2415	10.1016/j.jtha.2024.05.035	Commento/editoriale di commento
73	Environmental health and clinicians: time to promote more action.	Di Ciaula A, Mannucci PM , Portincasa P.	Internal and Emergency Medicine	2024	19	5	1203	1207	10.1007/s11739-024-03688-3	Review/linee Guida
74	Single-cell transcriptomic analysis to identify endomembrane regulation of metalloproteins and motor proteins in autoimmunity.	Abeni E, Cocola C, Croci S, Martino V, Piscitelli E, Gualtierotti R , Pelucchi P, Tria V, Porta G, Troschel F, Greve B, Nano G, Tomilini A, Kehler J, Gerovska D, Mazzaccaro D, Götte M, Arauzo-Bravo MJ, Carlo S, Zucchi I, Reinbold R.	Advances in Protein Chemistry and Structural Biology	2024	141	-	299	329	10.1016/bp.scbs.2024.03.007	Review/linee Guida
75	Real-world experience of rIX-FP prophylaxis at dosing intervals of 14 days or more in adult patients with haemophilia B in Italy - Results from IDEAL Part B.	Coppola A, Peyvandi F , Banov L, Cultrera D, Margaglione M, Tosetto A, Valdrè L, Schiavetti I, Loraschi A, Castaman G; Ideal Study Group.	Haemophilia	2024	30	4	1067	1070	10.1111/hae.15074	Lettera con dati
76	Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A.	Malec L, Peyvandi F , Chan AKC, Königs C, Zulfikar B, Yuan H, Simpson M, Álvarez Román MT, Carcao M, Staber JM, Dunn AL, Chou SC, d'Oiron R, Albisetti M, Demissie M, Santagostino E, Yarramaneni A, Wong N, Abad-Franch L, Gunawardena S, Fijnvandraat K; XTEND-Kids Trial Group.	New England Journal of Medicine	2024	391	3	235	246	10.1056/NEJMoa2312611.	Trial Profit
77	Rare inherited coagulation disorders: no longer orphan and neglected.	Mohsenian S, Mannucci PM, Menegatti M, Peyvandi F .	Research and Practice in Thrombosis and Haemostasis	2024	8	4			10.1016/j.rpth.2024.102460.	Review/linee Guida

78	Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS).	Fischer K, Lassila R, Peyvandi F , Gatt A, Gouw SC, Hollingsworth R, Lambert T, Kaczmarek R, Carbonero D, Makris M; European HAemophilia Safety Surveillance (EUHASS) participants.	Research and Practice in Thrombosis and Haemostasis	2024	8	4			10.1016/j.rpth.2024.102461.	Multicentrico NO PROFIT
79	International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology.	Rezende SM, Neumann I, Angchaisukri P, Awodu O, Boban A, Cuker A, Curtin JA, Jivvandraat K, Gouw SC, Gualtierotti R , Makris M, Nahuelhual P, O'Connell N, Saxena R, Shima M, Wu R, Rosendaal FR.	Journal of Thrombosis and Haemostasis	2024	22	9	2629	2652	10.1016/j.jth.2024.05.026	Review/linee Guida
80	Public regulation of private pharmacies in the European Union: time for a logical solution for retail distribution.	Garattini L, Nobili A, Mannucci PM.	Internal and Emergency Medicine	2024	19	6	1525	1528	10.1007/s11739-024-03691-8	Lettera opinion
81	The role of inflammation and antithrombin supplementation on thromboelastographic parameters during veno-venous ECMO for respiratory failure.	Meli A, De Falco S, Novembrino C, Boscolo Anzoletti M , Arcadipane A, Panarello G, Occhipinti G, Grasselli G, Panigada M.	Perfusion	2024	39	1 Suppl	665	765	10.1177/02676591241237637	Multicentrico NO PROFIT
82	Risk of harm to people with haemophilia from the 2023 WHO Essential Medicines List.	Pierce GF, O'Mahony B, Kaczmarek R, Skinner MW, Makris M, Peyvandi F , Srivastava A, Hermans C; World Federation of Hemophilia Coagulation Products Supply, Safety, and Access Committee (CPSSAC).	Lancet Haematology	2024	11	9	e638	e640	10.1016/s2352-3026(24)00223-0	Commento/editoriale di commento
83	von Willebrand disease.	Seidzadeh O , Eikenboom JCI, Denis CV, Flood VH, James P, Lenting PJ, Baronciani L , O'Donnell JS, Lillcrap D, Peyvandi F.	Nature Reviews Disease Primers	2024	10	1			10.1038/s41572-024-00536-8.	Review/linee Guida
84	The seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi-center analysis of 719 disease episodes.	Jacobs JW, Stanek CG, Booth GS, Symeonidis A, Shih AW, Allen ES, Gavrilaki E, Grossman BJ, Pavenski K, Moorehead A, Peyvandi F , Agosti P , Mancini I , Stephens LD, Raval JS, Mingot-Castellano ME, Crowe EP, Daou L, Pai M, Arnold DM, Marques MB, Henrie R, Smith TW, Sreenivasan G, Siniard RC, Wallace LR, Yamada C, Duque MA, Wu Y, Harrington TJ, Byrnes DM, Bitsani A, Davis AK, Robinson DH, Eichbaum Q, Figueroa Villalba CA, Juskevitch JE, Kaiafa G, Kapsali E, Klapper E, Perez-Alvarez I, Klein MS, Kotsiou N, Lalayanni C, Mandala E, Aldarweesh F, Alkhatib R, Fortuny L, Mellios Z, Papalexandri A, Parsons MG, Schlueter AJ, Tormey CA, Wellard C, Wood EM, Jia S, Wheeler AP, Powers AA, Webb CB, Yates SG, Bouzid R, Coppo P, Bloch EM, Adkins BD.	American Journal of Hematology	2024	99	11	2063	2074	10.1002/ajh.27458.	Multicentrico NO PROFIT
85	Gene therapy for people with Haemophilia B: a proposed care delivery model in Italy.	Castaman G, Di Minno G, Simioni P, Molinari AC, Siragusa S, Baldacci E, La Mura V , Lupi A, Grazzi EF, Peyvandi F.	Journal of Thrombosis and Haemostasis	2024	22	11	3084	3096	10.1016/j.jth.2024.07.029	Articolo originale
86	Acquired Hemophilia A after SARS-CoV-2 Immunization: A Narrative Review of a Rare Side Effect.	Castelli R, Gidaro A, Manetti R, Castiglia P, Delitala AP, Mannucci PM , Pasca S.	Vaccines (Basel)	2024	12	7	709		10.3390/vaccines12070709	Review/linee Guida
87	"Antiphospholipid antibody solid phase-based assays: problems and proposed solutions for the 2023 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for antiphospholipid syndrome": comment.	Tripodi A.	Journal of Thrombosis and Haemostasis	2024	22	8	2371	2372	10.1016/j.jth.2024.03.029	Commento/editoriale di commento
88	Caplacizumab improves clinical outcomes and is well tolerated across clinically relevant subgroups of patients with immune-mediated thrombotic thrombocytopenic purpura.	Pavenski K, Scully M, Coppo P, Cataland S, Knöbl P, Peyvandi F , Kremer Hovinga JA, de la Rubia J, Khan U, Marques AP, Gunawardena S.	Research and Practice in Thrombosis and Haemostasis	2024	8	5			10.1016/j.rpth.2024.102512	Multicentrico Profit
89	Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: expert guidance for clinical practice.	La Mura V , Cardinale V, De Cristofaro R Prof, De Santis A, Di Minno G, Fabris L, Marra F, Morisco F Prof, Peyvandi F , Pompili M, Santoro C, Zanon E, Castaman G.	Blood Advances	2024	8	22	5725	5734	10.1182/bloodadvances.2024013750	Review/linee Guida
90	Optimizing long-term joint health in the treatment of hemophilia.	Gualtierotti R , Giachi A , Suffritti C , Bedogni L, Franco F, Poggi F, Mascetti S, Colussi M, Ahmetovic D, Begnozzi V , Boccalandro EA , Solimeno LP, Peyvandi F.	Expert Review of Hematology	2024	17	10	713	721	10.1080/17474086.2024.2396617	Review/linee Guida
91	The management of liver disease in people with congenital bleeding disorders: guidance from EAHAD, EHC, ISTH, WFH.	LA Mura V , Colombo M, Foster GR, Hernandez P, Miesbach W, Klamroth R, Pierce GF, O'Mahony B, Lim MY, Hernandez-Gea V, Makris M, Peyvandi F.	Journal of Thrombosis and Haemostasis	2024	22	12	3629	3639	10.1016/j.jth.2024.08.018	Review/linee Guida
92	Pharmacokinetics of Efmoroctocog alfa by Two-Compartment Model Highlights Hemophilia A Patients with Biphasic Decay, Long Mean Residence Time, and Beta Half-Life.	Morfini M, Peyvandi F , Mancuso ME, Marchesini E, Tagliaferri A, Gualtierotti R , Castaman G, Pollio B, Santoro C, Banov L, Napolitano M, Preti PS, Santoro RC, Coppola A, Linari S, Santagostino E, Bernardi F.	Journal of Clinical Medicine	2024	13	17			10.3390/jcm13174986.	Articolo originale
93	Main features of ischemic stroke in patients with acute immune-mediated thrombotic thrombocytopenic purpura.	Truma A , Mancini I , Agosti P , Artoni A , Giannotta JA , Ferrari B , De Leo P , Peyvandi F.	Thrombosis Research	2024	243	November 2024			10.1016/j.thromres.2024	Articolo originale
94	Omalizumab for the Treatment of Chronic Spontaneous Urticaria in Adults and Adolescents: An Eight-Year Real-Life Experience.	Calzari P, Chiei Gallo A, Barei F, Bono E, Cugno M , Marzano AV, Ferrucci SM.	Journal of Clinical Medicine	2024	13	18			10.3390/jcm13185610.	Articolo originale
95	High risk of thrombosis recurrence in people with idiopathic or only locally caused non-cirrhotic splanchnic vein thrombosis: is it time for guidelines' revision.	Primignani M, Tosetti G, Artoni A.	Hepatobiliary Surgery and Nutrition	2024	13	4	699	702	10.21037/hbsn-24-292.	Lettera con dati
96	Fibro-adhesive Bursitis: A Novel Sonographic Finding in Adhesive Capsulitis Patients and a Proposal of Management.	Vita F, Gualtierotti R , Miceli M, Tedeschi R, Origlio F, Cavallo M, Galletti S, Stella SM, Guerra E, Donati D, Faldini C.	Rheumatology and Therapy	2024	11	6	1519	1532	10.1007/s40744-024-00716-8	Articolo originale
97	Evans syndrome: Disease awareness and clinical management in a nationwide ITP-NET survey.	Fattizzo B, Carrai V, Crugnola M, Baldacci E, Bellini M, Bosi C, Buzzatti E, Caramazza D, Carli G, Carpenedo M, Clissa C, Danesin C, De Paolis MR, Giannotta JA , Innao V, Marchetti M, Markovic U, Morotti A, Napolitano M, Patriarca A, Pettine L, Poloni A, Rivolti E, Rossi E, Santeramo TM, Santoro C, Zannier ME, Zaja F, Cantoni S, Palandri F, De Stefano V.	European Journal of Haematology	2024	113	4	472	476	10.1111/ejh.14256	Articolo originale
98	Exploring the Impact of Sex and Gender in Brain Function: Implications and Considerations.	Gualtierotti R , Bressi C, Garavaglia B, Brambilla P.	Advances in Therapy	2024	41	12	4377	4383	10.1007/s12325-024-03016-3	Articolo originale
99	A novel gene editing lexicon strategy for the haemophilia community: Research plan for development and preliminary results.	Hermans C, Valentino LA, Thornburg CD, Unzu C, Kay MA, Peyvandi F , Smith P, Miesbach W, McKeown W, Pierce GF, Khair K, Pipe SW, Starcevic K, Pillai M, Jones M, Chiao M, Antonino I, Kessler C.	Haemophilia	2024	30	6	1272	1280	10.1111/hae.15108	Articolo originale
100	Gut Microbiome Diversity and Composition Correlates With Time in the Therapeutic Range in Patients on Warfarin Treatment: A Pilot Study.	Agosti P , Kouraki A, Dionisi T, Addolorato G, D'Innocenzo L, Sorrentino S, De Maio F, De Candia E, Blanco-Miguez A, Bazzani D, Bonadiman A, Tonidandel G, Bolzan M, Gianniello F , Passamonti SM , Abbattista M , Valdes AM, Bucciarelli P , Peyvandi F , Menni C.	Arteriosclerosis Thrombosis and Vascular Biology	2024	44	12	2659	2661	10.1161/ATVBAHA.124.321490	Lettera con dati
101	Comparative Investigation of Thromboelastometry and Thrombin Generation for Patients Receiving Direct Oral Anticoagulants or Vitamin K Antagonists.	Tripodi A , Capecchi M, Scalabrino E , Clerici M, Scimeca B , Agosti P , Bucciarelli P , Artoni A , Peyvandi F.	Diagnostics (Basel)	2024	14	22			10.3390/diagnostics14225553.	Articolo originale
102	Therapies for Chronic Spontaneous Urticaria: Present and Future Developments.	Asero R, Calzari P, Valentini S, Cugno M.	Pharmaceuticals (Basel)	2024	17	11			10.3390/ph17111499.	Review/linee Guida

103	Inhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH study	Miri S, Rosendaal FR, Kavakli K, Eshghi P, Moghaddam SM, Scardo S, Habibpanah B, Elalfy M, Halimeh S, Nicolò G, Gökçebay D, Özbek N, Celkan T, Mohammadi A, Karimi M, Shahsavani A, Yilmaz B, Albayrak C, Gunes B, Kaya Z, Ay Y, Akbayram S, Sarper N, Mannucci PM, Peyvandi F; PUP-SWITCH Study Group.	Research and Practice in Thrombosis and Haemostasis	2024		8	8			10.1016/j.rpth.2024.102595	Multicentrico NO PROFIT
104	Mitochondrial function in patients affected with fibromyalgia syndrome is impaired and correlates with disease severity.	Macchi C, Giachi A , Fichtner I, Pedretti S, Puttini PS, Mitro N, Corsini A, Ruscica M, Gualtierotti R.	Scientific Reports	2024		14	1			10.1038/s41598-024-81298-x.	Articolo originale
105	Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENE8-1 trial.	Leavitt AD, Mahlangu J, Raheja P, Symington E, Quon DV, Giermasz A, López Fernández MF, Kenet G, Lowe G, Key NS, Millar CM, Pipe SW, Madan B, Chou SC, Klamroth R, Mason J, Chambost H, Peyvandi F , Majerus E, Pepperell D, Rivat C, Yu H, Robinson TM, Ozelo MC.	Research and Practice in Thrombosis and Haemostasis	2024		8	8			10.1016/j.rpth.2024	Trial Profit
106	Thrombotic thrombocytopenic purpura: 100 years of research on Moschowitz syndrome	Cataland S.R.; Coppo P.; Scully M.; Lämmle B., on behalf of the International Working Group on Thrombotic Thrombocytopenic Purpura (Agosti P.; Mancini I.; Peyvandi F.)	Blood	2024		144	11	1143	1152	10.1182/blood.2023022277	Multicentrico Collaborators
107	Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis	Nicoară-Farcău O.; Han G.; Rudler M.; Angrisani D.; Monesillo A.; Torres F.; Casanovas G.; Bosch J.; Lv Y.; Dunne P.D.J.; Hayes P.C.; Thabut D.; Fan D.; Hernández-Gea V.; García-Pagán J.C.; pre-emptive TIPS individual data metanalysis, International Variceal Bleeding Study and Baveno Cooperation Study groups (La Mura V)	Hepatology	2024		79	3	624	635	10.1097/HEP.0000000000000613	Multicentrico Collaborators
108	Mortality during the SARS-CoV-2 Pandemic: A Comparative Analysis between Lombardy in Italy and Israel	Najjar-Debbiny R.; Nobili A.; Mannucci P.M. ; Barnett-Griness O.; Saliba W.; Adir Y.; Antonella Galbussera A.; Tettamanti M.; D'Avanzo B.; Harari S.	Journal of Clinical Medicine	2024		13	16			10.3390/jcm13164766	Articolo originale
109	Patterns of C1-Inhibitor Plasma Levels and Kinin-Kallikrein System Activation in Relation to COVID-19 Severity. . 2024 Nov 21;14(12):1525. doi: PMID:	Berra S, Parolin D, Suffritti C , Folcia A, Zanichelli A, Gusso L, Cogliati C, Riva A, Gidaro A, Caccia S.	Life (Basel)	2024		14	12			10.3390/life14121525.	Articolo originale
110	Stratified analyses refine association between TLR7 rare variants and severe COVID-19.	Boos J, van der Made CI, Ramakrishnan G, Coughlan E, Asselta R, Löscher BS, Valenti LVC, de Cid R, Bujanda L, Julià A, Pairo-Castineira E, Baillie JK, May S, Zametica B, Heggemann J, Albillos A, Banales JM, Barretina J, Blay N, Bonfanti P, Buti M, Fernandez J, Marsal S, Prati D, Ronzoni L, Sacchi N; Spanish/Italian Severe COVID-19 Sequencing group (Peyvandi F) ; GenOMICC Investigators; Schultze JL, Riess O, Franke A, Rawlik K, Ellinghaus D, Hoischen A, Schmidt A, Ludwig KU.	Human Genetics and Genomics Advances	2024		5	4			10.1016/j.xhgg.2024.100323.	Multicentrico Collaborators